UK drug major GSK has entered into a ‘strategic partnership’ with MaRS Innovation, a Canadian group focused on harnessing the commercial potential of the discovery pipelines of 16 top Toronto academic institutions in its network.
Unlike other strategic partnerships announced this week , GlaxoSmithKline’s (GSK) new collaboration is designed to establish an innovation fund to support the commercialisation of promising translational research.
